<DOC>
	<DOCNO>NCT01958814</DOCNO>
	<brief_summary>randomize double-blind control study parallel group Salbutamol β2 mimetic short-acting administer nebulization study . During administration , non invasive ventilation patient continue .</brief_summary>
	<brief_title>Beta Agonist Nebulization Non Invasively Ventilated COPD Patients : Safety , Therapeutic Efficacy Range .</brief_title>
	<detailed_description>Randomization focus treatment administer ( placebo salbutamol ) . After first phase , switch set patient , retain blind administer salbutamol ( receive placebo first phase ) placebo ( receive salbutamol ) .</detailed_description>
	<mesh_term>Respiratory Insufficiency</mesh_term>
	<mesh_term>Albuterol</mesh_term>
	<criteria>Patient 18 year old Patient BPCO , define : irreversible obstructive syndrome and\or different argument ( history , symptom , physical examination , thoracic radiography , gas blood ) Decompensation BPCO form acute respiratory failure No argument dominant acute leave cardiac insufficiency Consent sign patient Patient national health assurance Contraindications invasive ventilation Patient volunteer realization spirometry Precautions use ß2 mimetic ( engrave hyperthyroidism ) Under guardianship patient protection justice Pregnant patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>